[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334027-105":59,"doc-detail-334027-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","real-world-treatment-patterns-resource-utilization-and-costs-in-biliary-tract-cancers-in-the-usa","Real-world treatment patterns, resource utilization and costs in biliary tract cancers in the USA","","Aim: To evaluate real-world treatment patterns, survival, and healthcare-resource utilization in US patients with advanced biliary tract cancers (BTC) receiving systemic therapy. Patients & methods: Claims data from the Healthcare Integrated Research Database (HIRD-R) linked to clinical data from the Cancer Care Quality Program (Jan 1, 2015–Sep 30, 2020). Results: Among 413 patients, 84.5% received gemcitabine-based first-line therapy; 46% received second-line and 16.5% third-line. Mortality was 53% with about 70% having at least one inpatient visit. Conclusions: Survival was poor and resource use and costs rose as treatment lines progressed.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-treatment-patterns-resource-utilization-and-costs-in-biliary-tract-cancers-in-the-usa/334027/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-treatment-patterns-resource-utilization-and-costs-in-biliary-tract-cancers-in-the-usa/334027.png","ImageObject",300,407,{"name":92,"@type":93},"Sage","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study aim for advanced biliary tract cancers (BTC) in the USA?","Question",{"text":112,"@type":113},"To assess real-world treatment patterns, survival outcomes, and healthcare-resource utilization in US patients with advanced BTC receiving systemic therapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were treatment lines distributed among the 413 patients?",{"text":117,"@type":113},"84.5% received gemcitabine-based first-line therapy, 46% received second-line therapy, and 16.5% received third-line therapy.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about resource use and costs as treatment progressed?",{"text":121,"@type":113},"Approximately 70% of patients had at least one inpatient visit, and total mean all-cause costs per patient per month increased from $19,589 for first-line to $33,534 for third-line therapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334027,1790432068,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":4},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","FUTURE ONCOLOGY  \n2024, VOL. 20, NO. 34, 2625–2636  \n[https://doi.org/10.1080/14796694.2024.2379237](https://doi.org/10.1080/14796694.2024.2379237)  \nRAPID COMMUNICATION     \nReal-world treatment patterns, resource utilization and costs in biliary tract cancers in the USA  \nLiya Wanga, Mukul Singhalb, Adriana Valderramaa, Bal Nepalb, Shital Kamblea, Madhulika Eluric, Usha Malhotraa,  \nAbby Siegela, Michael Grabnerb, Shilpi Swamid and Milind Javle* , c  \na Merck & Co., Inc., Rahway, NJ, USA; bCarelon Research, Wilmington, DE, US; cMD Anderson Cancer Center, Houston, TX, US; dMSD (UK) Ltd., London, UK  \nABSTRACT  \nAim: To evaluate real-world treatment patterns, survival and healthcare-resource utilization in US patients with advanced biliary tract cancers (BTC) receiving systemic therapy.  \nPatients & methods: This study used claims data from the Healthcare Integrated Research Database (HIRD􀀂R) linked to clinical data from the Cancer Care Quality Program (January 1, 2015–September 30, 2020) .  \nResults: Of 413 patients, 84.5% received gemcitabine-based first-line (1L) treatment, 46% received second-line treatment, and 16.5% received third-line (3L) treatment. All-cause mortality was 53% and approximately 70% of patients had ≥ 1 inpatient visit. The total mean per-patient-per-month all-cause costs were $19,589 for 1L and $33,534 for 3L treatment.  \nConclusion: Results showed poor survival, significant resource use and high costs as treatment line progresses for patients with advanced BTC.  \nPLAIN LANGUAGE SUMMARY  \nOur research explored which treatments US patients with advanced biliary tract cancers (BTC) received and how long they lived for. We analyzed information from a US database, called the Healthcare Integrated Research Database (HIRD􀀂R), which holds information related to healthcare insurance claims. Out of 413 patients in the database, 84.5% were initially given a combination treatment involving a chemotherapy called gemcitabine. We also found that 46% of patients received a type of second treatment (also known as second-line therapy), and 16.5% received a third treatment (third-line therapy) . During treatment, around 70% of patients needed to stay in hospital at least once. The cost of healthcare was more expensive for patients receiving later lines of therapy, with the average monthly cost per patient for first-line treatment being $19,589 and thirdline treatment being $33,534 . Furthermore, just over half of the 413 patients died from any causes, showing the poor outlook these patients face. This information is important for understanding the real-world management of patients with BTC, so that their care can be improved in the future.  \nARTICLE HISTORY  \nReceived 12 March 2024 Accepted 9 July 2024  \nKEYWORDS  \nbiliary tract cancer; chemotherapy; healthcare utilization; real world; survival; treatment patterns  \n1. Introduction  \nBiliary tract cancers (BTC), which include gallbladder cancer (GBC) and cholangiocarcinoma (intrahepatic cholangiocarcinoma [IHC] and extrahepatic cholangiocarcinoma [EHC]), are a group of rare, heterogeneous, aggressive malignancies with poor survival rates [1,2] . Globally, over the last two decades (1997–2017), the incidence and mortality of BTC have increased by 76% and 65% respectively, predominantly driven by a rise in IHC [2–4] .  \nIn the US, approximately 23,000 people are diagnosed with BTC each year [5] . Between 2001 and 2015, the overall incidence of cholangiocarcinoma was estimated to be  \n1.26 per 100,000 people per year [6]. However, this may bean underestimation as IHC and EHC epidemiologic data are often reported in conjunction with hepatocellular cancers and GBC, respectively [2]. The most recent pooled epidemiologic estimations for EHC and GBC date from 2021, with 12,000 new cases and 4,000 deaths [2] .  \nThe therapeutic options for patients with localized disease include liver resection, radiotherapy and liver transplantation, but most patients with BTC (60–70%) present w","cbCaiodLOzAilEas","https://ap.wps.com/l/cbCaiodLOzAilEas","pdf",1558114,12,"English","# Introduction\n## Epidemiology and disease burden\n## Treatment landscape and unmet needs\n# Abstract\n## Aim\n## Patients & methods\n## Results\n## Conclusion","[{\"question\":\"What was the study aim for advanced biliary tract cancers (BTC) in the USA?\",\"answer\":\"To assess real-world treatment patterns, survival outcomes, and healthcare-resource utilization in US patients with advanced BTC receiving systemic therapy.\"},{\"question\":\"How were treatment lines distributed among the 413 patients?\",\"answer\":\"84.5% received gemcitabine-based first-line therapy, 46% received second-line therapy, and 16.5% received third-line therapy.\"},{\"question\":\"What did the study find about resource use and costs as treatment progressed?\",\"answer\":\"Approximately 70% of patients had at least one inpatient visit, and total mean all-cause costs per patient per month increased from $19,589 for first-line to $33,534 for third-line therapy.\"}]","Real-world treatment patterns, resource utilization and costs in biliary tract cancers in the USA | PDF",1790005057]